You are using an old version of Internet Explorer. For better performance, we recommend
using Google Chrome, Firefox, Safari, or Internet Explorer V9 or above to visit this web site..
The cBioPortal for Cancer Genomics provides visualization, analysis and download of large-scale cancer genomics data sets.
Patient-specific view for TCGA endometrial cancer case TCGA-BK-A0CC.
The most prominent or most interesting genomic alteration events from an individual tumor sample can now be browsed and analyzed in the portal.
Data source: TCGA Uterine Corpus Endometrioid Carcinoma.
Network of genomic alterations in Serous Ovarian Cancer.
Network of BRCA1, BRCA2 and all altered neighbors, as identified in the TCGA ovarian cancer data set. Pink shading indicates frequency
of alteration across all patients (white = low frequency of alteration; red = high frequency of alteration); Green discs indicate rate of mutation across all patients.
Data source: TCGA Serous Ovarian Cancer Data Set.
OncoPrint of TP53 Pathway Alterations in Glioblastoma.
Example of TP53, MDM2, and MDM4 in Glioblastoma, visualized as an OncoPrint across all patients.
Data Source: TCGA Gliobastoma Data Set.
EGFR Amplifications in Gliobastoma.
Example of CNA v. mRNA Plot for EGFR in Glioblastoma Multiforme. CNA amplifications are accompanied by mRNA up-regulation.
Data Source: TCGA Gliobastoma Data Set.
Survival Analysis of BRCA Mutated v. Non-BRCA Mutated in Serous Ovarian Cancer.
BRCA-mutated cases show significantly better overall survival.
Data Source: TCGA Serous Ovarian Cancer Data Set.
Epigenetic Silencing of BRCA1 in Serous Ovarian Cancer
Example of Methylation v. mRNA Plot for BRCA1 in Serous Overian Cancer.
Data Source: TCGA Serous Ovarian Cancer Data Set.
Structural view of a PIK3R1 mutation in Glioblastoma
The D560Y variant of PIK3R1 in glioblastoma is shown on the PIK3R1 protein
structure (on the Mutation Assessor website). The mutated residue is shown in red.
Data Source: TCGA Glioblastoma Data Set.
TP53 mutations in ovarian cancer
TP53 is mutated in 95% of serous ovarian cancer patients. Some of these mutations are truncating, and
most of the missense mutations are predicted to have a high functional impact (prediction by Mutation Assessor).
"Whenever bench scientists ask me how they can look at TCGA data, I've never
had a good answer for them. Now I do. The cBio Portal meets a critical need--it is the
interface that the cancer research community needs to access the wealth of TCGA. Even as a
computational biologist, I use it to follow-up on genes of interest. It makes querying
the data much less painful."
– Postdoctoral Fellow, Oregon Health & Science University
"I would like to congratulate you and the team of the cBio portal.
It's just an amazing tool to work with, and we at Mass General really appreciate it."
– Research Fellow at Massachusetts General Hospital
"As a bench biologist with primary aim of determining gene aberrations in GBM, I found
your site absolutely fantastic! Thank you! I have to reiterate how awesome and user-friendly
your group has made this site - finally accomplishing the goal of having data easily accessible
and meaningful."
– Sr. Research Associate at Knight Cancer Institute/OHSU
"Thank you for your incredible resource that has helped greatly in accessing the TCGA
genomics data."
– Postdoctoral Fellow, Johns Hopkins University School of Medicine,
Dept Radiation Oncology and Molecular Radiation Sciences
"I have been enjoying the ease with which TCGA data can be extracted in R using your CGDS package.
Very nice work!"
– Sr. Software Engineer, Institute for Systems Biology
"Thank you for generating such an excellent software. It is very useful for our research."
– Research Fellow, Memorial Sloan-Kettering Cancer Center
"Thank you very much for providing and maintaining this great resource."
– Scientist, Discovery Bioinformatics, Biotechnology Company
"I want to thank you for the nice, useful and user-friendly interface you have generated
and shared with the community."
– Postdoctoral Fellow, Harvard Medical School, Children's Hospital Boston
"This portal is truly the greatest thing since sliced bread. I am making discoveries with it not only in glioblastoma, my primary focus, but in other cancers as well -- it?s all so easy with this fantastic tool. And I am enjoying showing it to my colleagues, whose jaws also drop. Thank you a thousand times over for this beautiful public resource. I am looking forward to citing this soon in an upcoming paper..."